Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales

)

Overview

• Rhythm Q3 2025 product revenue rises 54% yr/yr, driven by IMCIVREE sales
• Net income for Q3 2025 misses analyst expectations, larger loss reported
• FDA accepts sNDA for setmelanotide in acquired hypothalamic obesity, decision by Dec 20

Outlook

• Company expects FDA decision on sNDA by December 20, 2025
• Rhythm anticipates Q4 2025 results from Phase 2 trial in Prader-Willi syndrome
• Company updates 2025 Non-GAAP Operating Expenses guidance to $295 mln-$315 mln

Result Drivers

• U.S. SALES GROWTH - Revenue from U.S. sales increased 19% sequentially, driven by growth in IMCIVREE sales for BBS
• INTERNATIONAL SALES DECLINE - Revenue outside the U.S. decreased 21% sequentially due to ordering variability and a one-time pricing adjustment in France

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $51.29

Product mln

Revenue

Q3 Net Miss -$52.90 -$45.50

Income mln mln (11

Analysts

)

Q3 Basic -$0.82

EPS

Q3 -$52.65

Operatin mln

g Income

Analyst Coverage

• The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 14 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
• The average consensus recommendation for the pharmaceuticals peer group is “buy”
• Wall Street’s median 12-month price target for Rhythm Pharmaceuticals Inc is $121.50, about 6.4% above its November 3 closing price of $113.74

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)